close

Cynosure, Inc. develops and markets aesthetic treatment systems to the dermatology, plastic surgery, and general medical markets. Its systems incorporate a range of laser and other light-based energy sources, including Alexandrite, pulse dye, Nd:Yag, and diode lasers, as well as intense pulsed light. The company offers 18 different aesthetic treatment systems, including the Apogee Elite system for hair removal; the Cynergy system for the treatment of vascular lesions; the TriActive LaserDermology system for the temporary reduction of the appearance of cellulite; the Affirm and Affirm CO2 systems for anti-aging, including treatments for wrinkles, skin texture, skin discoloration and skin tightening; the Smartlipo and Smartlipo MPX systems for LaserBodySculpting for the removal of unwanted fat; and Accolade system for the removal of benign pigmented lesions, including pigmented lesions known as Nevus of Ota and Nevus of Ito, as well as multi-colored tattoos. Cynosure sells its products through a direct sales force in North America, 4 European countries, Japan, and China, as well as through international distributors in 55 other countries. The company was founded in 1991 and is based in Westford, Massachusetts.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	18.47
Volume	44914
Volume Avg	56374
52 Week High	19.44
52 Week Low	8.84
PE	N/A
PE (group average)	39
EPS Year	-0.23
EPS change Q/Q	-40%
EPS change Q/Q Yr ago	-94.74%
EPS change Q/Q next Q est	1000%
EPS change Y/Y	-258%
REV change Q/Q	16.75%
REV change Q/Q Yr ago	15.54%
EPS next Q est	0.07
EPS next Y est	0.48
Divident Annual	0.00
Dividend Yield	0%